Rita Nanda

17.4k citations
209 papers · 6.5k · 5 hit papers · h-index 34

Impact in

  • Oncology top 0.5%
    • Cancer Immunotherapy and Biomarkers
    • HER2/EGFR in Cancer Research
    • Cancer Cells and Metastasis
    • Breast Cancer Treatment Studies
    • Cancer Genomics and Diagnostics

Papers in

    • Cancer Immunotherapy and Biomarkers 46
    • HER2/EGFR in Cancer Research 38
    • Cancer Treatment and Pharmacology 27
    • PARP inhibition in cancer therapy 19
    • Advanced Breast Cancer Therapies 56

Rita Nanda

193 papers receiving 6.4k citations

Rita Nanda's Hit Papers

Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database 2023 · 91 citations
910+7+14Years since publication250500750

Peers

Rita Nanda
Comparison fields: 5 of 114
  • Oncology 3.6k
  • Cancer Research 2.0k
  • Immunology 933
  • Pulmonary and Respiratory Medicine 1.1k
  • Radiology, Nuclear Medicine and Imaging 530
Replace Roberto Salgado with:
Roberto Salgado Belgium
Aurelia Noske Germany
Valsamo Anagnostou United States
Alexandra Léary France
Theodoros Foukakis Sweden
Michael J. Pishvaian United States
Laura D. Wood United States
Rinat Yerushalmi Israel
Joaquı́n Mateo United Kingdom
Roberto Hegg Brazil
Rita Nanda relative to Roberto Salgado Belgium Roberto Salgado's profile →
Citations per field
00.5×1.5×
Roberto Salgado · 1×
Citations per year

Countries citing papers authored by Rita Nanda

Since Specialization
Citations

This map shows the geographic impact of Rita Nanda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rita Nanda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rita Nanda more than expected).

Fields of papers citing papers by Rita Nanda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rita Nanda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rita Nanda. The network helps show where Rita Nanda may publish in the future.

Co-authors

The 25 scholars most cited alongside Rita Nanda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rita Nanda Line = papers co-authored together Rita Nanda links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 209 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Hit paper breakdown →
2005839
2
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
Hit paper breakdown →
2018583
3
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
Hit paper breakdown →
2018482
4
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Hit paper breakdown →
2018357
5 2009288
6 2005192
7 2013191
8 2013169
9 2017158
10 2008157
11 2021155
12 2013155
13 2019144
14 2005143
15 2017138
16 2019116
17 2015109
18
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database
Hit paper breakdown →
202391
19 201790
20 201587

About Rita Nanda

Rita Nanda is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 209 papers that have together received 6.5k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (56 papers), Cancer Immunotherapy and Biomarkers (46 papers), HER2/EGFR in Cancer Research (38 papers), Breast Cancer Treatment Studies (35 papers), Cancer Treatment and Pharmacology (27 papers), Cancer Genomics and Diagnostics (23 papers), PARP inhibition in cancer therapy (19 papers) and Radiopharmaceutical Chemistry and Applications (14 papers). The work is most often cited by research in Oncology (3.6k citations), Cancer Research (2.0k citations), Immunology (933 citations), Pulmonary and Respiratory Medicine (1.1k citations) and Radiology, Nuclear Medicine and Imaging (530 citations). Rita Nanda has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Olufunmilayo I. Olopade, Charles M. Perou, Chad Livasy, Gamze Karaca, Dominic T. Moore, Maria Tretiakova, Peter Schmid, Dezheng Huo, Tatyana A. Grushko and Eric P. Winer. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Breast Cancer Research and Treatment and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact